Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
|Videos|June 11, 2019
Dr. Arbour on the Latest Data for Checkpoint Inhibitors for Lung Cancer in 2019
Author(s)Kathryn Cecilia Arbour, MD
Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Advertisement
Cancer Network spoke with Kathryn Cecilia Arbour, MD, medical oncologist at Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in the treatment of cancer. Dr. Arbour presented this data during an educational session at ASCO 2019.
Advertisement
Related to this article
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5